UPDATED NOVEMBER 5, 2024 TO INCLUDE APPROACH FOR PRIORITIZING TRIAL-ELIGIBLE INDIVIDUALS.
updated Jaguar gene therapy community letter
Previous
Previous
Pioneering Progress: Insights from ASGCT 2025 on the Future of PMS Therapeutics
Next
Next